Its abnormal expression is involved in the pathology of various diseases, including asthma, diarrhea, cystic fibrosis, hypertension, ischemic stroke, and cancer.[34] As a result, both CFTR and ANO1 are considered emerging therapeutic targets for diarrhea and other epithelium‐originated diseases, and some inhibitors are currently under clinical trials.[34, 35] In our study, we observed increased levels of Cftr and Ano1 in mouse small intestine, colon, and gut organoids after T‐bet overexpression, consistent with the diarrhea and dehydration phenotypes. This evidence concerns the gene TBX21 and asthma.